Publications by authors named "Ashley Beekman"
Article Synopsis
- Researchers examined treatment options for primary CNS lymphoma in adult patients, focusing on five chemotherapy regimens that include high-dose methotrexate (HD-MTX).
- Out of 204 patients in the study, a significant majority (93%) received various combinations of HD-MTX and other drugs, with the MPV/Ara-C regimen showing the best results in progression-free and overall survival rates.
- The study concluded that using tailored treatment strategies can boost recovery rates, especially for older patients not suited for more aggressive therapies.
Arsenic trioxide is an essential component of therapy for acute promyelocytic leukaemia (APL) and is currently dosed on actual body weight with no upper limit. Arsenic-induced neurotoxicity is a well-recognised complication; however, there is uncertainty about its relationship to arsenic dose and obesity. We conducted a large multicentre retrospective study of 487 patients with APL treated with arsenic-based therapy across 23 sites in Australia from 2008 to 2023.
View Article and Find Full Text PDFArticle Synopsis
- Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma with varied clinical outcomes, often requiring multiple treatment lines, but resulting in shorter disease control periods over time.
- Novel treatments like chimeric antigen receptor T-cell therapies and bispecific antibodies may be effective but are usually given late in the treatment process, potentially missing chances to help patients with more aggressive forms of the disease.
- A study of 389 patients over 10 years revealed that mortality from MCL increases with each treatment line, highlighting the need for earlier trials of innovative therapies for high-risk patients, especially older individuals and those relapsing early.
PARP inhibitor-induced torsades de pointes in long QT syndrome: a case report.
Eur Heart J Case Rep
February 2020
Background: Poly ADP-ribose polymerase (PARP) inhibitors target pathogenic mutations in chemotherapy-resistant malignancies. PARP inhibitors cause modest dose-dependent QT prolongation in the setting of a normal baseline QT interval.
Case Summary: We describe a case of PARP inhibitor-induced torsades de pointes (TdP) in an 86-year-old gentleman prescribed rucaparib due to chemotherapy-resistant, metastatic prostate cancer with pre-existing long QT, with an apparent dose-dependent increase in QT interval.